Table 1.
Demographics of 430 prostate cancer patients belonging to the intermediate risk class
| Continuous variables | Mean (SD) | Median (IQR) |
|---|---|---|
| Age (years) | 64.8 (6.6) | 65 (61–70) |
| Body mass index; BMI (kg/m2) | 25.7 (3.3) | 25.6 (23.6–27.8) |
| Endogenous testosterone; ET (ng/dL) | 434.3 (169.6) | 418.9 (314.8–520.4) |
| ET density (ETD; ng/(dL × mL)) | 12.1 (8.1) | 10.4 (6.9–14.4) |
| Prostate-specific antigen; PSA (ng/mL) | 7.2 (3.5) | 6.4 (4.9–8.9) |
| PSA density (PSAD; ng/(mL × mL)) | 0.19 (0.11) | 0.16 (0.12–0.24) |
| Prostate volume (PV; mL) | 42.6 (17.9) | 39 (830–51) |
| Biopsy positive cores; BPC (%) | 35.4 (20.8) | 30 (20–50) |
| BPC density (BPCD; %/mL) | 1.0 (0.8) | 0.8 (0.42–1.35) |
| Prostate weight; PW (grams) | 4.3 (18.5) | 50 (41–63.5) |
| Tumor load (TL; %) | 20.3 (13.9) | 19 (10–25) |
| Categorical variables | Number (%) | |
|---|---|---|
| ISUP at biopsy | ||
| ISUP 1 | 69 (16) | |
| ISUP 2 | 240 (55.9) | |
| ISUP 3 | 121 (28.1) | |
| Clinical T stage (cT) | ||
| cT1c | 259 (60.2) | |
| cT2 (a/b) | 171 (31.8) | |
| ISUP at pathology | ||
| ISUP < 4 (no tumor upgrading) | 362 (84.2) | |
| ISUP > 3 (tumor upgrading) | 68 (15.8) | |
| Pathologic tumor stage (pT) | ||
| pT2 | 340 (79.1) | |
| pT3a | 44 (10.2) | |
| pT3b | 46 (10.7) | |
| Surgical margins status (SM) | ||
| Negative | 319 (74.2) | |
| Positive | 111 (25.8) | |
| Pathologic nodal stage (pN) | ||
| pN0 | 313 (72.8) | |
| pN1 | 25 (5.8) | |
| pNx | 92 (21.4) | |
| Unfavorable disease at surgical pathology (*) | 122 (28.4) |
SD standard deviation, IQR interquartile range, ISUP International Society of Urologic Pathology tumor grade group formulation
*Tumor upgrading and/or upstaging at surgical pathology in removed prostates